Thrombocytopenia Following Isolated Surgical Aortic Valve Replacement With Inspiris Resilia Bioprosthesis.

Aims: Thrombocytopenia (TCP) following aortic valve replacement (AVR) is a significant concern, with varying degrees of platelet count reduction observed postoperatively. This phenomenon occurs more frequently in patients undergoing surgical biological AVR compared to those receiving mechanical AVR or transcatheter aortic valve implantation (TAVI). This study aimed to investigate the incidence of TCP following surgical AVR with the Inspiris Resilia bioprosthesis compared with Carpentier Magna Ease valve.

Methods: The study retrospectively collected data from 144 patients who underwent isolated AVR between January and December 2023. Patients received either the Inspiris Resilia or the Carpentier Magna Ease valve. Platelet counts were evaluated from admission to discharge, and statistical analyses were performed to identify significant variables correlated to post-operative TCP.

Results: Patients receiving the Inspiris Resilia valve had higher platelet counts from postoperative day 1-3 compared to those with the Carpentier Magna Ease valve. The incidence of moderate-to-severe TCP was significantly lower in the Inspiris Resilia group. However, no significant differences in clinical outcomes, such as bleeding events and blood transfusion rates, were observed between the two groups.

Conclusions: The study showed that the Inspiris Resilia valve is associated with a lower incidence of moderate-to-severe TCP compared to the Carpentier Magna Ease valve. These findings underscore the potential benefits of utilizing the Inspiris Resilia valve to mitigate the risk of TCP post-AVR. Further research with larger cohorts is warranted to validate these results and explore the underlying mechanisms.